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ABSTRACT
Background. A novel data-driven cluster analysis identified distinct pathogenic patterns in C3-glomerulopathies and
immune complex-mediated membranoproliferative glomerulonephritis. Our aim was to replicate these observations in an
independent cohort and elucidate disease pathophysiology with detailed analysis of functional complement markers.
Methods. A total of 92 patients with clinical, histological, complement and genetic data were involved in the study, and
hierarchical cluster analysis was done by Ward method, where four clusters were generated.
Results. High levels of sC5b-9 (soluble membrane attack complex), low serum C3 levels and young age at onset (13 years)
were characteristic for Cluster 1 with a high prevalence of likely pathogenic variations (LPVs) and C3 nephritic factor,
whereas for Cluster 2—which is not reliable because of the small number of cases—strong immunoglobulin G staining, low
C3 levels and high prevalence of nephritic syndrome at disease onset were observed. Low plasma sC5b-9 levels, decreased
C3 levels and high prevalence of LPV and sclerotic glomeruli were present in Cluster 3, and patients with late onset of the
disease (median: 39.5 years) and near-normal C3 levels in Cluster 4. A significant difference was observed in the incidence of
end-stage renal disease during follow-up between the different clusters. Patients in Clusters 3–4 had worse renal survival
than patients in Clusters 1–2.
Conclusions. Our results confirm the main findings of the original cluster analysis and indicate that the observed, distinct
pathogenic patterns are replicated in our cohort. Further investigations are necessary to analyse the distinct biological and
pathogenic processes in these patient groups.
Keywords: C3-glomerulopathy, C3-glomerulonephritis, complement, dense deposit disease, membranoproliferative
glomerulonephritis
226 | N. Garam et al.
INTRODUCTION
Membranoproliferative glomerulonephritis (MPGN), character-
ized by mesangial hypercellularity, endocapillary proliferation
and capillary wall thickening with double contour formation, is
a pathological pattern detected by light microscopy on kidney
biopsies [1]. Recent improvements in our understanding of the
disease pathogenesis, with the recognition of the pivotal role of
complement alternative pathway (AP) [2], led to the description
of complement-mediated (C3-glomerulopathy, C3G) and
immune complex-mediated MPGN (IC-MPGN) forms [3]. C3G
presents with microscopic haematuria, proteinuria and renal
failure, with dominant (minimum two-order magnitude stron-
ger C3 staining than any other immunoreactant) C3 stain on im-
munofluorescence microscopy, and is caused by the
dysregulation of the AP due to the presence of variations of
complement genes [Complement Factor H (CFH), Complement
Factor I (CFI), Membrane cofactor protein (CD46), Complement
Factor B (CFB), Thrombomodulin (THBD)] [1, 4–6], or by autoanti-
bodies [C3 nephritic factor (C3NeF), anti-Factor H, anti-C3, anti-
Factor B and C4 nephritic factor (C4NeF)] against complement
proteins [7–11]. Despite thorough analysis of potential risk fac-
tors, complement-related predisposing factors in several
patients with C3G remain unidentified. C3G is divided according
to electron microscopy, where C3-glomerulonephritis (C3GNs)
usually has less dense mesangial, subendothelial and subepi-
thelial deposits, whereas dense deposit disease (DDD) is charac-
terized by electron-dense intramembranous deposits.
Despite improved understanding of disease pathogenesis,
several questions still remain unanswered, including deviation
between pathological and clinical presentations, hampered dif-
ferentiation between C3GN and DDD (sometimes with IC-
MPGN) or even changes in the characteristic patterns if repeated
biopsies are done [3, 12, 13]. Even more importantly, the as-
sumption that AP dysregulation is the most characteristic dif-
ferentiating feature between immunoglobulin (Ig)-negative and
Ig-positive, MPGN does not seem to be powerful enough since a
large portion of patients with Ig-positive MPGN may be positive
for C3NeF, or show decreased C3 levels with normal C4 [1, 14].
Taking all these limitations and considerations into account,
Iatropoulos et al. [15] recently explored the potential utility of
unsupervised cluster analysis to generate clinically meaningful
subgroups of C3G/IC-MPGN patients. In their study, four distinct
clusters were generated based on the clinical, histological, com-
plement and genetic parameters. Patients in Clusters 1 and 2
had elevated terminal pathway activation marker (sC5b-9) lev-
els with low C3 concentrations, whereas patients with dense
deposits, decreased C3 but only moderately elevated sC5b-9 fell
into Cluster 3. Patients in Clusters 1–3 had a similarly high prev-
alence of C3NeF and/or presence of likely pathogenic variation
(LPVs) in complement genes, which was in contrast to Cluster 4,
where C3 activation in glomeruli (not in circulation), presence
of sclerotic glomeruli and absence of LPVs or C3NeF were char-
acteristic. Interestingly, each cluster included patients with IC-
MPGN, DDD or C3GN, strengthening the overlap between these
entities. Notably, reclassification of C3GN, DDD and IC-MPGN
patients by cluster analysis proved to be better at predicting re-
nal survival, a result pointing to the feasibility of the ultimate
goal of efficient patient stratification for complement-
modulating therapies. However, as such unsupervised mathe-
matical approaches are completely dependent on the studied
cohort and on the variable set, validation in independent
cohorts is essential.
Therefore, our aim was to validate the observations of
Iatropoulos et al. [15] in an independent cohort. We enrolled 92
patients with pathologically diagnosed IC-MPGN/C3G, repeated
the cluster analysis by analysing the same variable set
(Supplementary data, Table S1), with the generation of four
clusters, and observed very similar patterns to that of the origi-
nal study. In addition, we tested further complement parame-
ters to better characterize ongoing pathophysiology in the
different clusters.
MATERIALS ANDMETHODS
A total of 92 patients with histologically proven C3G or IC-MPGN
were enrolled in the study from 34 centres in Central and
Eastern Europe (Supplementary data, Figure S1). Clinical and
histological data were collected from clinicians, and genetic
analysis (CFH, CFI, CD46, C3, CFB and THBD) was performed by
Sanger sequencing (Supplementary data, Table S2). Serum C3,
C4 concentration was determined by turbidimetry. Classical
pathway activity was measured by haemolytic test [16]. Other
complement parameters [AP activity, sC5b-9, anti-Factor H,
anti-Factor B, anti-C3, anti-C1q, C4d, Bb, Factor D (FD)] were
measured using home-made or commercially available ELISA
kits. C3NeF activity was detected using haemolytic test [17].
Detailed methods are presented in Supplementary
materials.
RESULTS
Generation of clinical patterns by cluster analysis
Clinical characteristics (Tables 1 and 2) of the patients and com-
parison of the two cohorts (Supplementary data, Figure S2) are
summarized in Supplementary results. Similar to the study of
Iatropoulos et al. [15], four distinct clusters were generated
(Supplementary data, Figure S3). Forty-five patients were
regrouped into Cluster 1, 4 patients into Cluster 2, 17 subjects
into Cluster 3 and 26 patients into Cluster 4 (Tables 3 and 4). In
our analysis Cluster 3, including mainly young adults with
lower sC5b-9 levels and higher prevalence of sclerotic glomeruli,
was completely separated from the remaining clusters.
Thereafter, Cluster 4 was separated from Clusters 1 and 2,
which includes adult patients with later disease onset and
higher C3 levels (Supplementary data, Figure S3).
Cluster 1 was characterized by low C3 levels (median 0.5 g/L),
very high sC5b-9 (median 540 ng/mL) levels and high prevalence
of LPVs and C3NeF. The median age of onset was 13 years. Renal
impairment and creatinine levels were low in that cluster at the
time of onset. On light microscopy, no sclerotic glomeruli or
crescents were seen, the strong C3 staining was not isolated
and Ig staining was also seen in Cluster 1 on immunofluores-
cence microscopy, in concordance with the original study of
Iatropoulos et al. [15].
The four patients in Cluster 2 had the strongest glomerular
staining for IgA, IgG and C1q, with substantial crescent forma-
tion, three of them had nephrotic-range proteinuria; hence, the
descriptive characteristics are very similar to those published
by Iatropoulos et al. However, due to the low case number, we
excluded these patients from further analysis.
In Cluster 3, the lowest sC5b-9 levels (median 250 ng/mL)
were observed, compared with other clusters, along with mod-
erately decreased C3 concentration (median 0.77 g/L) and with
high prevalence of LPVs (Figure 1). On light microscopy, the
highest degree of interstitial fibrosis, interstitial inflammation
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and the highest prevalence of sclerotic glomeruli were seen
with low prevalence of crescents, compared with the other
clusters.
In Cluster 4, the median age of onset (39.5 years) was the
highest compared with the other clusters, and this cluster was
also characterized by near-normal C3 levels (median 0.93 g/L;
Table 3 and Figure 1) and with lower prevalence of intramem-
branous deposits (P¼ 0.046). The prevalence of thrombotic
microangiopathy (TMA) was the highest in this cluster in Italian
cluster [15]. We have only two patients with data for TMA, but
they were excluded because of missing data, which is why we
could not examine this aspect of Cluster 4.
The key pathogenic features of the different clusters in the
two cohorts are shown in comparative manner in
Supplementary data, Figure S4.
Decision tree analysis was done to select the minimum set of
features to predict membership of patients in the clusters
(Figure 2), and predictor variables were ranked according to their
classification importance (Supplementary data, Table S3). The top
two classifiers were the presence and extent of sclerotic glomeruli
and age at diagnosis. Using three cut-points of these variables, all
but one patient were correctly classified into Clusters 1, 3 and 4.
Variable ranking indicated that besides age at diagnosis and extent
of glomerular sclerosis, the most important predictor variables for
cluster membership were the presence of interstitial fibrosis, inter-
stitial inflammation, arteriolar sclerosis and sC5b-9 level.
No difference was observed with regard to the occurrence or
distribution of LPVs between the different clusters, but LPVs af-
fecting C3 and CFH were identified only in Cluster 1. The gener-
ated clusters did not show significant connection with the
original histology-based diagnosis (Supplementary data, Table
S4) although patients with C3GN and IC-MPGN fall mainly into
Clusters 1 and 4.
Prognostic significance of the clusters
Clinical relevance of the clusters was evaluated by analysis of
their association with renal outcome. During the follow-up
period, we managed to collect data on the development of end-
stage renal disease (ESRD), defined as estimated glomerular fil-
tration rate decrease to <15 mL/min/1.73 m2 with or without
renal replacement therapy (such as haemodialysis, peritoneal
dialysis or kidney transplantation). Ultimately, 10 out of the 79
successfully followed patients progressed to ESRD including 5
patients with acute kidney injury at the time of diagnosis but
later temporary improvement of kidney function. Renal out-
come was found to be worse in Clusters 3 and 4 compared with
Cluster 1 with Kaplan–Meier analysis (P< 0.05 for Clusters 3 ver-
sus 1 and Clusters 4 versus 1), indicating that patients with
higher age at diagnosis, more prevalent glomerular sclerosis at
diagnosis and lower prevalence of C3NeF and/or LPV have infe-
rior renal outcome. There was no difference in renal survival
according to the histology groups (Figure 3). We have data of
patients’ treatment strategy at the time of diagnosis, which
may affect renal survival. Going through the data, most of the
patients received antihypertensive drugs [angiotensin-convert-
ing enzyme-I and angiotensin-receptor blockers (ARB) and
immunosuppressants (steroid, cyclophosphamide and myco-
phenolate mofetil). In some cases, plasmatherapy and renal re-
placement therapy were indicated at the time of diagnosis. No
relevant differences were seen between patients’ initial therapy
in different clusters (Supplementary data, Table S5). The various
treatment modifications during follow-up period were not
collected.
Complement activation and regulation in relation to
clinical patterns
The findings of the cluster analysis motivated us to examine an
extended set of complement parameters. Due to the association
of high sC5b-9 levels and C3 consumption with clusters
(Table 3), we measured additional complement proteins, path-
way activities and activation markers (Table 5). Significantly
lower classical pathway (CP) (P¼ 0.001) and alternative pathway
(AP) (P¼ 0.02) activity, along with decreased FD concentrations
(P¼ 0.006) were observed in Cluster 1, where C1q levels were
also the lowest. These results together with decreased C3 and
Table 1. Clinical characteristics of patients with histologically proven diagnosis of C3G or IC-MPGN
Variables C3GN,
n¼ 37
DDD,
n¼ 11
IC-MPGN,
n¼44
All,
n¼ 92 P-valueb
Sex, % men 17 (46) 3 (27.3) 26 (59.1) 46 (50) 0.14
Age at diagnosis, years 23.5 (13–39) 17 (13.5–27.5) 15 (9–33) 16 (10–33) 0.1
Microhaematuria, present 24 (64.8) 8 (72.7) 24 (54.5) 56 (60.9) 0.44
Gross haematuria, present 7 (19) 2 (18.2) 11 (25) 20 (21.7) 0.76
Non-nephrotic proteinuria, present 18 (48.6) 4 (36.4) 22 (50) 44 (48.5) 0.71
Nephrotic syndrome, present 15 (40.5) 7 (63.6) 21 (47.7) 43 (47.3) 0.39
Renal impairment, present 13 (35.1) 4 (36.4) 15 (34.1) 32 (35.2) 0.98
Renal failure, present 4 (10.8) 1 (9) 6 (13.6) 11 (12.1) 0.88
Creatinine, lmol/L 86 (53–240) 79 (52–121) 82 (55–168) 83 (54–196) 0.89
Trigger, present 5 (13.5) 3 (27.3) 7 (16) 15 (16.5) 0.55
Familiarity, present 5 (13.2) 0 (0) 5 (11.4) 10 (10.9) 0.44
Serum C3, g/L 0.68 (0.34–1.05) 0.5 (0.25–0.86) 0.69 (0.31–0.96) 0.67 (0.33–0.99) 0.93
Serum C4, g/L 0.28 (0.19–0.41) 0.21 (0.16–0.36) 0.2 (0.13–0.25)a 0.23 (0.17–0.32) 0.02
Low serum C3 with normal serum C4 19 (51.3) 7 (63.6) 18 (41) 44 (47.8) 0.34
sC5b-9, ng/mL 421 (271–661) 509 (327–1069) 375 (243–731) 406 (261–690) 0.7
LPV carriers 7 (20) 2 (18.2) 9 (21.4) 18 (20.5) 0.96
C3NeF positivity, present 7 (19.4) 5 (45.4) 11 (25) 23 (25.3) 0.2
LPV carriers and/or C3NeF positivity, present 11 (29.7) 5 (45.4) 17 (38.6) 33 (35.8) 0.18
The data are given as median and interquartile range or number and percentages. Reference range: C3, 0.9–1.8 g/L; C4, 0.15–0.55 g/L; sC5b-9, 110–252 ng/mL.
aSignificantly different from C3GN.
bP-values are given as the results of Chi-square or Kruskal–Wallis tests of the patients with IC-MPGN, C3GN and DDD.
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C4 levels in Cluster 1 indicating overactivation and consump-
tion of CP/AP compared with the Clusters 3 and 4.
Concentrations of the complement activation split products
C4d, Bb and C3a were low and did not show any significant dif-
ference among the different clusters.
C3NeF positivity was more prevalent in Cluster 1; therefore,
additional complement autoantibodies including anti-C1q, anti-
Factor H, anti-Factor B and anti-C3 were also determined.
Cluster 1 captured 11 out of 13 anti-C1q-positive patients
(P¼ 0.018), whereas no difference in the prevalence of anti-
Factor H, anti-C3 and anti-Factor B among the four clusters was
observed. Multiple positivity for the examined autoantibodies
was observed more frequently in Cluster 1. We did not find any
association between the studied parameters and the histology-
based groups (Supplementary data, Table S6).
DISCUSSION
Current classification of MPGN is based on immunofluorescence
microscopy and classifies patients as C3G/IC-MPGN [3].
Recently, an unsupervised, data-driven method was applied by
Iatropoulos and associates for a cohort of MPGN patients to see
whether clinically meaningful groups can be identified based
on clinical, biochemical, histological or genetic data [15]. This
new statistical approach generated clusters with small within-
cluster, as opposed to large between-cluster, differences.
The clusters showed clear associations with AP abnormalities,
additional pathogenic features and risk of progression to ESRD.
As was pointed out in an editorial [18] commenting the results
of Iatropoulos et al., repetition of these observations in an
independent cohort is essential to validate if such clusters
exist or not.
Table 2. Histological characteristics of patients with histologically proven diagnosis of C3G or IC-MPGN
Variables C3GN,
n¼ 37
DDD,
n¼ 11
IC-MPGN,
n¼ 44
All,
n¼ 92 P-valuee
Time onset to biopsy, month 0 (0–2.03) 0 (0–4) 0 (0–0.55) 0 (0–0.88) 0.59
Light microscopy
Sclerotic glomeruli, % 6.8 (0–39) 0 (0–4) 0 (0–20) 4 (0–23) 0.16
Crescent, % 0 (0–9) 0 (0–7) 0 (0–9) 0 (0–8) 0.65
Degree of mesangial proliferation
0/1/2/3a 7/9/11/10 1/4/5/1 6/13/19/6 14/26/35/17 0.56
Medianþ 25–75th range 2 (1–3) 2 (1–2) 2 (1–3) 2 (1–2)
Degree of endocapillary proliferation
0/1/2/3a 7/9/15/6 5/3/2/1 21/7/10/6 33/19/27/13 0.17
Medianþ 25–75th range 2 (1–2) 1 (0–2) 1 (0–2) 1 (0–2)
Degree of interstitial inflammation
0/1/2/3a 14/13/7/3 2/5/4/0 14/15/6/3 38/33/17/1 0.67
Medianþ 25–75th range 1 (0–2) 1 (1–2) 0.5 (0–1) 1 (0–1)
Degree of interstitial fibrosis
0/1/2/3a 13/13/8/3 2/6/2/1 24/8/12/0 39/27/22/4 0.055
Medianþ 25–75th range 1 (0–2) 1 (1–2) 0 (0–2) 1 (0–2)
Arteriolar sclerosis, present 13 (35) 3 (27.3) 10 (22.7) 26 (28.3) 0.46
Immunofluorescence microscopy
C3
0/1/2/3a 0/0/8/29 0/0/1/10 2/3/17/22 2/3/26/61 0.047
Medianþ 25–75th range 3 (3–3)b 3 (3–3) 2.5 (2–3) 3 (2–3)
IgA
0/1/2/3a 32/4/0/0 7/4/0/0 22/9/4/9 61/17/4/9 0.002
Medianþ 25–75th range 0 (0–0) 0 (0–1) 0.5 (0–2)c,d 0 (0–1)
IgG
0/1/2/3a 28/9/0/0 5/6/0/0 14/9/9/12 47/24/9/12 <0.0001
Medianþ 25–75th range 0 (0–0) 1 (0–1) 1 (0–3)c,d 0 (0–1)
IgM
0/1/2/3a 24/12/0/0 5/6/0/0 5/14/18/7 34/32/18/7 <0.0001
Medianþ 25–75th range 0 (0–1)b,c 1 (0–1) 2 (1–2) 1 (0–2)
C1q
0/1/2/3a 27/8/0/0 3/7/0/0 11/9/13/8 41/24/13/9 <0.0001
Medianþ 25–75th range 2 (0–2)b,c 1 (0–1) 2 (0–2) 1 (0–1.5)
Electron microscopy
Mesangial deposit, present 28 (75.7) 8 (72.7) 25 (56.8) 61 (66.3) 0.18
Subepithelial deposit, present 15 (40.5) 5 (45.4) 21 (47.7) 41 (44.6) 0.8
Subendothelial deposit, present 22 (57.4) 5 (45.4) 30 (68.2) 57 (62) 0.35
Intramembranous deposit, present 15 (40.5) 11 (100)b,d 18 (40.9) 44 (47.8) 0.001
The data are given as median and interquartile range or number and percentages if not otherwise stated. Some patients have missing values in the following data: IgA,
IgM, C1q immunofluorescence staining.
aDegree of light microscopy, immunofluorescence findings were defined using scales 0–3.
bSignificantly different from IC-MPGN.
cSignificantly different from DDD.
dSignificantly different from C3GN.
eP-values are given as the results of Chi-square or Kruskal–Wallis tests of the patients with IC-MPGN, C3GN and DDD.
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The aim of our study was to replicate the unsupervised hier-
archical cluster analysis made by Iatropoulos et al. [15] in an in-
dependent C3G/IC-MPGN cohort and to validate the existence of
clinically meaningful clusters. We recruited 92 patients and de-
termined the same clinical, biochemical, histological and ge-
netic parameters as in the original study [15]. Our independent
cohort seemed to be appropriate for validation study since the
most important characteristics were similar to the original co-
hort (Supplementary data, Figure S2). With unsupervised, data-
driven clustering method, four clusters were generated yielding
Clusters 1, 3 and 4 with sufficiently high patient numbers,
whereas Cluster 2 with only four patients was excluded from
further analysis. Clusters 1, 3 and 4 showed clear associations
with clinical, biochemical or histological variables with a very
similar pattern to that of Iatropoulos et al. (Supplementary data,
Figure S4). Clinical relevance of the clusters was demonstrated
by the significant association of Clusters 3 and 4 with develop-
ment of ESRD during follow-up (Figure 3).
In the study of Iatropoulos et al. [15], a three-step algorithm
was created to assign patients into different clusters.
Unfortunately, we have no data to differentiate between highly
electron-dense ribbon-like and granular deposits in basement
membrane. That is why the minimum data set necessary to
predict membership in the clusters was determined by decision
tree analysis. Based on the presence and extent of sclerotic glo-
meruli, and age at onset, we could divide the patients into four
clusters (Figure 2). Patients with higher percentages of sclerotic
glomeruli and older age fall into Clusters 3 and 4, and have infe-
rior renal survival. These findings are consistent with the well-
known fact that renal survival is connected with the chronicity
of the glomerular lesions, but the pathomechanism of the
resulting pathological image is not known. It is noteworthy and
would be important to explore why the pattern of some
important clinical and complement parameters show associa-
tion with these clusters and with outcome, too.
The patterns of clinical and pathogenetic factors of the dif-
ferent clusters were very similar in our study to those in
Iatropoulos et al. Cluster 1 identified patients with very high
sC5b-9 and decreased C3 levels, along with the high prevalence
of LPVs and/or C3NeF in younger patients. Patients in Cluster 3
were typically young adults characterized also by complement
consumption (decreased C3) but lower sC5b-9 levels, whereas
the histological picture was more severe as indicated by higher
degree of interstitial inflammation, fibrosis and presence of
sclerotic glomeruli. Based on these results, we could not un-
equivocally match the current Cluster 3 to the Italian Cluster 3.
The importance of the difference is also supported by the differ-
ent renal survival of Cluster 3. Cluster 4 included adults with
normal levels of C3, lack of severe complement activation and
inferior renal survival.
Beyond the similarities, some differences were also noted
between our study and that of Iatropoulos et al. [15], the most
important being some discrepancies in histology. We enrolled
patients from several centres, without the option of centralized
second review of biopsy. Rather, aggregate evaluation of biopsy
descriptions was done by a structured questionnaire.
Furthermore, the mean ages in Clusters 3 and 4 are higher by
10 years in our study, and this may explain why the prevalence
of sclerotic glomeruli is also higher in Cluster 3. Cluster 3 differs
in our study from the original study in additional aspects too,
including the lack of crescents and lower C3NeF prevalence.
The difference of C3NeF prevalence between the two studies
could be explained by the different method of the detection of
C3NeF activity. In contrast to the Italian study where purified
IgG was used for the detection, we used patients’ sera following
the protocol of Rother [17]. This fact can make this slight differ-
ence between the prevalence of C3NeF.
Table 3. Clinical characteristics of patients according to the classification by cluster analysis
Variables Cluster 1,
n¼ 45
Cluster 2,
n¼ 4
Cluster 3,
n¼ 17
Cluster 4,
n¼ 26 P-value
N 45 4 17 26
Sex, % (men) 20 (44.4) 3 (75) 12 (70.6) 11 (42.3) 0.16
Age at diagnosis, years 13 (7–16) 9.5 (8–20) 25 (10–33) 39.5 (33–50)a,b <0.0001
Microhaematuria, present 27 (60) 2 (50) 11 (64.7) 16 (61.5) 0.94
Gross haematuria, present 9 (20) 2 (50) 4 (23.5) 5 (19.2) 0.93
Non-nephrotic proteinuria, present 24 (53.3) 1 (25) 7 (41.2) 12 (48) 0.68
Nephrotic syndrome, present 17 (37.7) 3 (75) 10 (58.8) 13 (52) 0.25
Renal impairment, present 9 (20)b 2 (50) 11 (64.7) 10 (40) 0.003
Renal failure, present 4 (8.9) 1 (25) 1 (5.9) 5 (20) 0.27
Creatinine, lmol/L 61 (49–79)b 215 (50–569) 170 (63–229) 166 (92–285) 0.005
Trigger, present 12 (26.7)c 1 (25) 1 (5.9) 1 (4) 0.02
Familiarity present (%) 4 (8.9) 0 (0) 4 (23.5) 2 (7.7) 0.21
Serum C3, g/L 0.5 (0.23–0.84)c 0.64 (0.29–0.93) 0.77 (0.4–0.92) 0.93 (0.66–1.17) 0.02
Serum C4, g/L 0.19 (0.12–0.3)b 0.35 (0.18–0.6) 0.25 (0.21–0.4) 0.24 (0.2–0.3) 0.01
Low serum C3 with normal serum C4, present 20 (44.4) 3 (75) 11 (64.7) 10 (38.5) 0.22
sC5b-9, ng/mL 540 (332–1136)b 438 (275–724) 250 (189–404) 407 (261–500) 0.003
LPV carriers 10 (23.2) 0 (0) 3 (17.6) 5 (20.8) 0.89
C3NeF positivity, present 17 (38.6)c 1 (25) 2 (11.8) 3 (11.5) 0.02
LPV carriers and/or C3NeF positivity, present 21 (46.7) 1 (25) 4 (23.5) 7 (26.9) 0.21
The data are given as median and interquartile range or number and percentages. P-values are given as the results of Chi-square or Kruskal–Wallis tests of patients in
Clusters 1, 3 and 4. Reference range: C3 0.9–1.8 g/L; C4 0.15–0.55 g/L; sC5b-9 1110–252 ng/mL. Some patients have missing values in the following data: proteinuria, renal
impairment/failure, sC5b-9, LPV and C3NeF.
aSignificantly different from Cluster 1.
bSignificantly different from Cluster 3.
cSignificantly different from Cluster 4.
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Higher age, and lack of crescents but presence of sclerosis,
indicating advanced disease stage may explain the inferior re-
nal survival of patients in Cluster 3. Cluster 4 is best character-
ized by lack of systemic signs of complement activation and
consumption, but with intense glomerular C3 stain and inferior
survival. The answer to why patients in Clusters 3 and 4 have
advanced glomerular lesions and higher age at presentation
with inferior renal survival, and whether these features are re-
lated to the molecular pathophysiology, remains elusive today.
The presence of complement consumption and a high sC5b-9
level in Cluster 1 prompted us to explore additional comple-
ment biomarkers and autoantibodies to understand the under-
lying pathophysiology. We found that Cluster 1 encompassed
most of the patients with anti-C1q autoantibodies. Remarkably,
2/11 and 5/11 anti-C1q-positive patients in Cluster 1 were
double or triple positive for additional complement autoanti-
bodies listed in Table 5. The observation that different comple-
ment autoantibodies occur together in Cluster 1 (P¼ 0.043 when
compared with Clusters 3 and 4) also raises the possibility of
strong polyclonal response and epitope spreading towards com-
plement proteins. In addition to the autoantibodies presented
in this study (Table 5), presence of C4NeF also seems to be more
prevalent in Cluster 1 (N. Garam et al., unpublished work).
We acknowledge the potential limitations of our study.
Some of our observations and conclusions stem from under-
powered analysis and may suffer from Type I error. However,
since this is an independent replication study, and most of
the key observations and differences were similar in the two
studies, the appearance of false-positive decisions twice is
highly unlikely. In addition, our study lacked centralized second
Table 4. Histological characteristics of patients according to the classification by cluster analysis
Variables Cluster 1,
n¼ 45
Cluster 2,
n¼ 4
Cluster 3,
n¼17
Cluster 4,
n¼ 26 P-valuee
Time onset to biopsy (months) 0 (0–0.69) 1.85 (0.15–4.91) 0 (0–0.6) 0 (0.46–2.1) 0.22
Light microscopy
Sclerotic glomeruli, % 0 (0–5) 0 (0–0) 60 (47–70)a,b 6 (0–19) <0.0001
Crescent, % 0 (0–4) 55 (46–62)a,b,c 0 (0–6) 0 (0–9) 0.06
Degree of mesangial proliferation
0/1/2/3d 5/11/18/11 1/1/2/0 2/3/6/4 4/11/9/2 0.34
Medianþ 25–75th range 2 (1–2) 1.5 (0.5–2) 2 (1–2) 1 (1–2)
Degree of endocapillary proliferation
0/1/2/3d 13/8/18/6 2/0/1/0 7/4/3/3 11/7/5/3 0.48
Medianþ 25–75th range 2 (0–2) 1 (0–2.5) 1 (0–2) 1 (0–2)
Degree of interstitial inflammation
0/1/2/3d 24/18/3/0 2/1/1/0 2/6/6/3 10/8/7/1 0.001
Medianþ 25–75th range 0 (0–1)b,c 0.5 (0–1.5) 2 (1–2)b 1 (0–2)
Degree of interstitial fibrosis
0/1/2/3d 27/15/3/0 2/1/1/0 1/3/10/3 9/8/8/1 <0.0001
Medianþ 25–75th range 0 (0–1)b,c 0.5 (0–1.5) 2 (2–2)b 1 (0–2)
Arteriolar sclerosis, present 3 (6.7)b,c 1 (25) 10 (58.8) 12 (46.2) <0.0001
Immunofluorescence microscopy
C3
0/1/2/3d 1/1/12/31 0/1/0/3 0/1/4/12 1/0/10/15 0.72
Medianþ 25–75th range 3 (2–3) 3 (2–3) 3 (2–3) 3 (2–3)
IgA
0/1/2/3d 28/9/3/5 2/1/0/1 12/3/0/1 19/4/1/2 0.89
Medianþ 25–75th range 0 (0–1) 0.5 (0–2) 0 (0–0.5) 0 (0–1)
IgG
0/1/2/3d 22/8/7/8 0/2/0/2 9/7/0/1 16/7/2/1 0.13
Medianþ 25–75th range 1 (0–2) 2 (1–3) 0 (0–1) 0 (0–1)
IgM
0/1/2/3d 14/16/10/5 1/3/0/0 7/5/2/2 12/8/6/0 0.5
Medianþ 25–75th range 1 (0–2) 1 (0.5–1) 1 (0–1) 1 (0–1.5)
C1q
0/1/2/3d 18/11/9/7 1/1/1/1 10/5/0/1 12/7/3/0 0.16
Medianþ 25–75th range 1 (0–2) 1.5 (0.5–2.5) 0 (0–1) 0 (0–1)
Electron microscopy
Mesangial deposit, present 30 (66.7) 2 (50) 12 (70.6) 17 (65.4) 0.93
Subepithelial deposit, present 24 (53.3) 3 (75) 7 (41.2) 7 (26.9) 0.09
Subendothelial deposit, present 31 (68.9) 3 (75) 10 (58.8) 13 (50) 0.28
Intramembranous deposit, present 24 (53.3) 2 (50) 11 (64.7) 7 (26.9)a 0.07
The data are given as median and interquartile range or number and percentages if not otherwise stated. Some patients have missing values in the following data: IgA,
IgM, C1q immunofluorescence staining.
aSignificantly different from Cluster 1.
bSignificantly different from Cluster 4.
cSignificantly different from Cluster 3.
dDegree of light microscopy, immunofluorescence findings were defined using scales 0–3.
eP-values are given as the results of Chi-square or Kruskal–Wallis tests of patients in Clusters 1, 3 and 4.
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look-up of biopsy results, potentially leading to higher variance
in histology-based scores. However, the most important cluster-
defining histological marker was presence and extent of
sclerotic glomeruli, a feature not prone to suffer from large
inter-observer differences. We could not distinguish between
granular and ribbon-like highly electron-dense intramembra-
nous deposits in our study because only intramembranous
highly electron-dense deposits were mentioned in most of the
pathology reports.
Considering the extremely low prevalence of C3G (2–3/1 000
000 people), large multicentre studies are essentials to confirm
the original studies of Iatropoulos et al. [15]. Although we could
not collect some data in exactly the same way as it was de-
scribed in the Italian study, this study is the first that managed
to collect enough patients to run this analysis again in a very
similar manner and this international collaboration allowed us
to validate the main findings of the original analysis in this rare
disorder. With the ultimate goal to support treatment decisions
for patients with these rare diseases, our results confirmed the
existence of Clusters 1 and 4. Patients in Cluster 1 are best char-
acterized by younger age, lack of glomerular sclerosis, high
prevalence of LPVs and autoantibodies, and signs of systemic
complement activation and consumption, hence, intense C5-
convertase activity. These signs support the presence of fluid-
phase dysregulation; hence, patients falling into Cluster 1 are
potential candidates for C5-targeted therapies. In contrast,
patients in Cluster 4 had no signs of systemic complement acti-
vation or consumption despite intense C3 deposition in the kid-
ney, indicating the presence of surface-limited complement
dysregulation. The fact that four out of five LPV carriers in
Cluster 4 carried LPVs in the genes of surface expressed cofac-
tors CD46 and THBD seems to support this idea. Therefore, the
proposition of Iatropoulos et al. to consider complement inhibi-
tors, targeting C3 activation products on cell surfaces (like TT30)
[19], seems to be rational and is also supported by our observa-
tions. Finally, despite independent validation of the original
observations [15], it is still a question whether this new, data-
driven, pathogenesis-connected classification can change the
histology-based classification in the long term, with the final
goal of better classification to support appropriate treatment
decisions.
SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
FIGURE 1: Scatterplots of age at diagnosis (A), serum C3 levels (B) and plasma sC5b-9 levels (C) across the different clusters. Horizontal lines show medians, whiskers
interquartile ranges of the groups. Horizontal dotted lines indicate reference range limits. For the comparison of Clusters 1, 3 and 4, Kruskal–Wallis analysis of variance
was used (panel A, P¼0.018; panel B, P¼0.003; panel C, P<0.0001) with Dunn’s post hoc test. *P<0.05.
FIGURE 2: Decision tree to assign patients into the different clusters. Analysis based on classification and regression model built to predict independent clusters as cat-
egorical variable, and on the same predictor variable set that was used for the cluster analysis (for details see Materials and methods section). Four patients in Cluster 2
were excluded from this analysis.
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FIGURE 3: Kaplan–Meier renal survival curves for groups of MPGN patients based on the histological diagnosis (A) or cluster (B). P-values of log-rank tests are indicated.
Cluster 2 was excluded from Kaplan–Meier analysis. To better visualize the renal survival of the patients, we stopped the curves at 6 years because of a shorter follow-
up in the majority of the cases. ICGN, immune complex-mediated MPGN.
Table 5. Additional complement factors, activation markers and autoantibodies in the different clusters
Variables Cluster 1 Cluster 2 Cluster 3 Cluster 4 P-value
Classical pathway activity, CH50/mL 30.5 (6.5–47)a 50 (10.75–69.75) 60 (32.5–62) 54 (36.5–54) 0.001
AP activity, % 7 (1–63)a 82.5 (18–103.5) 65 (16.5–84.5) 75 (19–97) 0.02
C1q antigen, mg/L 95 (73–123) 94 (75.75–131.8) 112.5 (96.75–136) 105 (79–117) 0.09
Anti-C1q positivity, present 11 (24.4)a 0 (0) 1 (5.9) 1 (3.8) 0.018
Anti-Factor H positivity, present 3 (7.1) 0 (0) 2 (11.8) 0 (0) 0.24
Anti-C3 positivity, present 4 (9.3) 1 (25) 0 (0) 0 (0) 0.14
Anti-Factor B positivity, present 2 (4.7) 1 (25) 2 (12.5) 1 (4.2) 0.47
Positivity for >1 complement autoantibodyb 5 (11.1)a 1 (25) 1 (5.8) 0 (0) 0.04
FD, mg/mL 1.4 (0.65–2.49)a,c 2.65 (0.76–5.19) 3.16 (2.37–4.4) 2.48 (1.28–4.66) 0.006
C4d, mg/mL 4.18 (3.05–7.51) 9.37 (7.32–10.83) 3.42 (2.73–9.04) 5.76 (3.31–10.06) 0.32
Bb, mg/mL 1.34 (0.85–2.09) 1.34 (0.69–3.58) 1.6 (1.19–2.08) 1.49 (1.03–2.84) 0.38
C3a, ng/mL 176 (98.5–229.1) 102 (77.46–223) 123 (68–174.7) 172 (105.5–244.5) 0.2
The data are given as median and interquartile range or number and percentages. P-values are given as the results of Chi-square or Kruskal–Wallis tests of patients in
Clusters 1, 3 and 4. Reference range: sC5b-9 110–252 ng/mL; C3a 70–270 ng/mL; C4d 0.7–6.3mg/mL; Bb 0.49–1.42mg/mL; FD 0.51–1.59 mg/mL. Some patients have missing
values in the following data: C1q antigen, anti-C1q, anti-FH, anti-C3 and anti-FB, FD, C4d, Bb, C3.
aSignificantly different from Cluster 4.
bOut of C3NeF, anti-C1q, anti-FH, anti-C3 and anti-FB .
cSignificantly different from Cluster 3.
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